Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer
作者： O. Guérin , P. Formento , C. Lo Nigro , P. Hofman , J. L. Fischel
DOI: 10.1007/S00432-007-0247-4
关键词: Sunitinib 、 Epidermal growth factor receptor 、 Sunitinib malate 、 Cancer research 、 Cancer 、 Docetaxel 、 Endocrinology 、 Tyrosine-kinase inhibitor 、 Prostate cancer 、 Internal medicine 、 Cetuximab 、 Medicine
摘要: Purpose Physiological and molecular findings indicate over-expression of HER proteins dysregulation neo-angiogenesis during progression advanced prostate cancer. The aim this study was to test a novel rational therapeutic approach by combining docetaxel with an EGFR-targeting agent (cetuximab) anti-angiogenic (sunitinib, SUTENT®).
springer.com
sci-hub.se 参考文章(31)
F K Engels, A Sparreboom, R A A Mathot, J Verweij, Potential for improvement of docetaxel-based chemotherapy: a pharmacological review British Journal of Cancer. ,vol. 93, pp. 173- 177 ,(2005) , 10.1038/SJ.BJC.6602698
C M Canil, I F Tannock, Is there a role for chemotherapy in prostate cancer British Journal of Cancer. ,vol. 91, pp. 1005- 1011 ,(2004) , 10.1038/SJ.BJC.6601850
Kristian Pietras, Douglas Hanahan, A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer Journal of Clinical Oncology. ,vol. 23, pp. 939- 952 ,(2005) , 10.1200/JCO.2005.07.093
Jean-Louis Fischel, Joseph Ciccolini, Patricia Formento, Jean-Marc Ferrero, G??rard Milano, Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine. Anti-Cancer Drugs. ,vol. 17, pp. 807- 813 ,(2006) , 10.1097/01.CAD.0000224444.23953.90
Daniel P. Petrylak, Future directions in the treatment of androgen-independent prostate cancer Urology. ,vol. 65, pp. 8- 12 ,(2005) , 10.1016/J.UROLOGY.2005.04.020
Patricia M LoRusso, Phase I studies of ZD1839 in patients with common solid tumors Seminars in Oncology. ,vol. 30, pp. 21- 29 ,(2003) , 10.1053/SONC.2003.50029
Ravikumar Aalinkeel, Madhavan P. N. Nair, Gerald Sufrin, Supriya D. Mahajan, Kailash C. Chadha, Ram P. Chawda, Stanley A. Schwartz, Gene Expression of Angiogenic Factors Correlates with Metastatic Potential of Prostate Cancer Cells Cancer Research. ,vol. 64, pp. 5311- 5321 ,(2004) , 10.1158/0008-5472.CAN-2506-2
E.A. Kingsley, B. Szymanska, K.T. Ow, V.W. Wen, K.L. MacKenzie, P.B. Vermeulen, P. Jackson, P.J. Russell, L.A. Perryman, J.M. Blair, Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo. Biochemical and Biophysical Research Communications. ,vol. 345, pp. 1207- 1214 ,(2006) , 10.1016/J.BBRC.2006.05.020
A Bozec, S Lassalle, J Gugenheim, J-L Fischel, P Formento, P Hofman, G Milano, Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126 British Journal of Cancer. ,vol. 95, pp. 722- 728 ,(2006) , 10.1038/SJ.BJC.6603308
James R. Tonra, Dhanvanthri S. Deevi, Erik Corcoran, Huiling Li, Su Wang, Francine E. Carrick, Daniel J. Hicklin, Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clinical Cancer Research. ,vol. 12, pp. 2197- 2207 ,(2006) , 10.1158/1078-0432.CCR-05-1682